Back to search
FDAFDA · Food and drugs·Recall number D-1184-2018

Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 2.5 mL Single-use Vial, Rx only, Sterile, Manufactured for: Hospira, Inc, Lake Forest, IL 60045 USA. NDC: 0409-1140-01

Published September 19, 2018 · Recall initiated: August 28, 2018

Summary

FDA records drug Class III recall D-1184-2018, published September 19, 2018 and initiated August 28, 2018. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 1,580 vials; Lot: Lot: DP602, 10/2018. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc.
Distributor
Nationwide USA
Lot
Lot: DP602, 10/2018
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 2.5 mL Single-use Vial, Rx only, Sterile, Manufactured for: Hospira, Inc, Lake Forest, IL 60045 USA. NDC: 0409-1140-01 recalled?

Yes. FDA published recall D-1184-2018 on September 19, 2018. Reported hazard: Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point

What should I do if I have this product?

Voluntary: Firm initiated · Letter